Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cladribine 2-CdA immunosuppressant data

Results of a Phase III trial in 48 patients with chronic progressive multiple sclerosis were published in

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE